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Abstract 
 
Background: The combination of cisplatin and 5-fluorouracil (PF) is currently considered a standard and effec-
tive regimen for the treatment of advanced head and neck carcinomas. The aim of this study was to evaluate the 
efficacy and safety of docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with unresectable head and neck 
carcinomas.  
 
Methods: Forty-six patients with previously untreated non-metastatic stage IV head and neck carcinomas were en-
rolled. All patients received three cycles of induction chemotherapy with docetaxel (75 mg/m
2), cisplatin (40 mg/m
2) 
(days 1-2), and 5-FU (500 mg/m
2, days 1-3), repeated every 21 days. Following induction chemotherapy, all patients 
underwent concurrent chemoradiotherapy using weekly cisplatin (30 mg/m
2) and a median total dose of 70 Gy was 
delivered. Clinical response rate and toxicity were the primary and secondary end-points of the study.  
 
Results: There were 31 men and 15 women. All patients had non-metastatic stage IV (T2-3N2-3 or T4N0-3) of 
disease. Overall and complete response rates were 74% and 24% respectively. Advanced T4 classification was 
associated with poorer response rate (p value=0.042). The major (grade 3-4) treatment-related toxicities were 
myelosuppression (78%), anorexia (13%), diarrhea (7%), emesis (11%) and stomatitis/pharyngitis (24%).  
 
Conclusion: In comparison with the data of historical published trials of the PF regimen, the TPF regimen was 
more effective. However, the TPF regimen appears to be associated with a higher incidence of major toxicities. 
Therefore, our limited findings support the TPF regimen as an alternative chemotherapeutic regimen for ad-
vanced head and neck carcinomas. 
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Introduction 
 
The squamous cell carcinomas of head and neck are 
the most frequent malignancies in this region.
1 The 
prognosis  of  these  tumors  is  directly  dependent  on 
their presenting stage. The early stage head and neck 
carcinomas  have  favorable  prognosis,  with  70%  to 
90% five-year survival rate after a standard treatment 
(surgery, radiotherapy or a combination of both), but 
unfortunately about two thirds of patients have locally 
advanced (stage III and IV) disease.
2 The prognosis 
for this group of patients is poor.
3 The treatment of 
choice for these patients was radiotherapy alone with 
5-year survival rate of less than 20%.
4,5 The replace-
ment  of  concurrent  chemoradiotherapy
6,7  instead  of 
radiotherapy alone is widely accepted, but induction 
chemotherapy has also been associated with a surviv-
al  benefit  and  could  be  a  valuable  treatment  op-
tion.
5,8,9  The  combination  of  cisplatin  and  5-
fluorouracil (5-FU), which is called the PF regimen, 
is the standard regimen for treatment of locally ad-
vanced carcinomas of the head and neck region and is 
effective  in  these  tumors.  There  were  several  new 
agents introduced in the last decade of the 20
th centu-
ry, in which the taxanes have shown great effective-
ness in the treatment of head and neck carcinomas by 
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addition of docetaxel to cisplatin and 5-FU (the TPF 
regimen); some phase II studies have revealed that it 
is more effective than the standard PF regimen.
10-14 
Therefore, we arranged a phase II study of the combi-
nation of docetaxel with cisplatin and 5-FU in a pa-
tient population consisting of locally advanced, non-
metastatic head and neck carcinomas. 
 
 
Materials and Methods  
 
This phase II study enrolled patients with newly di-
agnosed  locally  advanced  (T3-4,  and/or  N2-3,  M0) 
non-metastatic head and neck carcinomas. From April 
2001 to November 2005, 50 Patients with locally ad-
vanced head and neck carcinomas were qualified for 
enrollment in this study. Tumors of the nasopharyn-
geal origin were excluded. All patients had pathology 
proof  for  their  malignancies  and  they  were  locally 
advanced,  non-metastatic,  unresectable  with  WHO 
performance status of <2. All of them were between 
25 and 75 years old and none were treated previously. 
They  had  adequate  bone  marrow,  liver  and  renal 
function. The exclusion criteria were previous treat-
ment (chemotherapy or radiotherapy), any metastatic 
disease or another active malignancy, any radical sur-
gery previously in head and neck region for malig-
nancy, and active co-morbid disease such as uncon-
trolled diabetes or hypertension or chronic obstructive 
pulmonary  disease  requiring  hospitalization  during 
the previous year. The trial was approved by the local 
university Ethics Committee and all patients signed a 
written informed consent before therapy.  
Fifty patients were enrolled in the study but four of 
them were excluded due to poor cooperation. Surgery 
was performed four weeks after completion of chemo-
radiation. The clinical response rate and toxicity were 
the primary and secondary end-points of this study. 
The patients received three cycles of the TPF reg-
imen (docetaxel,  75  mg  per  square  meter  of  body-
surface area; cisplatin, 40 mg per square meter for the 
first two consecutive days of each cycle and bolus 5-
FU, 500 mg per square meter as bolus for the first 
three  consecutive  days  of  each  cycle)  as  induction 
chemotherapy, and after three to four weeks follow-
ing the last (third) cycle of induction chemotherapy, 
they were assigned to receive concurrent chemoradia-
tion.  They  received  weekly  cisplatin  (30  mg  per 
square meter per week) during the course of a con-
ventional radiotherapy course. The radiotherapy dose 
to primary disease and any other gross bulky tumor in 
the neck was between 65 and 70 Gy, which was admin-
istered with definitive and curative intent using 1.8 Gy 
dose per fraction per day, for 5 days per week. The un-
involved regions received 45-50 Gy, the operation was 
considered 6 to 8 weeks after the completion of chemo-
radiotherapy for the patients who had an advanced nodal 
disease (N2 or N3) on presentation or those who had 
residual disease after the course of treatment.  
Before  starting  therapy,  pretreatment  evaluation 
included a complete patient history and physical ex-
amination, computed tomography (CT) of the neck, 
magnetic  resonance  imaging  (MRI)  of  the  primary 
site,  and  chest  x-ray.  The  6th  edition  of  American 
Joint Committee on Cancer (AJCC), TNM 2002 stag-
ing system was used for staging disease. Complete 
laboratory  tests  included  a  complete  blood  count 
(CBC),  blood  serum  electrolytes,  creatinine,  blood 
urea nitrogen,  liver  function tests  (LFT),  and  renal 
function tests (RFT).  
The response to treatment was also assessed the 
same way after induction chemotherapy and 6 to 8 
weeks after the completion of the course of chemora-
diotherapy  and  in  the  regular  follow  up  period. 
Grades  of  Stomatitis/pharyngitis  were  determined 
based  on  the  Radiation  Therapy  Oncology  Group 
(RTOG) scoring criteria. CBC, LFT, and RFT were 
checked weekly. The grades of the hematologic toxic-
ities were also determined based on the RTOG scor-
ing  criteria.  A  complete  response  was  defined  as 
complete  resolution  of  all  clinically  evident  symp-
toms  of  the  disease  and  imaging  studies.  A  partial 
response was defined as at least 50% reduction in the 
tumor size and not meeting the criteria for complete 
response, and finally, a less than 50% tumor regres-
sion was considered as no clinical response.   
Clinical  response  rates  and  toxicities  were  the 
primary and secondary end-points of the study. Clini-
cal response rates and toxicities were compared be-
tween  the  variables  (sex,  age,  primary  sites,  stage, 
and  tumor  grade)  using  the  Chi-Square  or  Fisher’s 
Exact test when the cell expectation was less than six. 
P values less than 0.05 were considered significant. 
All  statistical  analyses  were  performed  with  SPSS 
software (Version 15.0, Chicago, IL, USA). 
 
 
Results 
 
From  April  2001  to  November  2005,  fifty  patients 
with acceptable inclusion criteria were enrolled, four 
of them did not complete their treatment program and TPF in head and neck carcinomas 
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finally the study was closed with 46 patients. There 
were 31  men and  15 women  and all  of them  had 
non-metastatic,  locally  advanced  (T2-3  N2-3  or 
T4N0-3) head and neck carcinomas (Table 1). At the 
time of data analysis, follow up period was at least 
24 months with a median of 36 months. There were 
26% (12/46) none response, 50% (23/46) partial and 
24%  (11/46)  complete  response  to  treatment.  Ad-
vanced T4 classification was associated with poorer 
response rate (p=0.042). The major (grade 3-4) treat-
ment-related  toxicities  were  myelosuppression 
(89%),  stomatitis/pharyngitis  (30%),  anorexia 
(13%), emesis (11%), and diarrhea (7%) (Table 2). 
Neutropenia was the most common hematologic ad-
verse effect, there was no treatment–related mortali-
ty, and most of the patients were treated in an outpa-
tient  setting  with  GCSF  support  and  prophylactic 
antibiotic therapy (in some cases), but there were 3 
patients (7%) who needed hospitalization due to fe-
brile neutropenia. Among non-hematologic adverse 
effects,  mucositis,  especially  in  oropharyngeal  re-
gion, was most common. 
Table 1: Patients characteristics 
Variables  Response  P value  Total 
No  Partial  Complete 
Sex 
   Male 
   Female 
 
8 
4 
 
 17 
6 
 
6 
5 
 
 
0.529 
 
 31 
 15 
Age 
   ≤60 years 
   >60 years 
 
7 
5 
 
 12 
 11 
 
7 
4 
 
 
0.811 
 
 26 
 20 
Primary site 
   Maxillary sinus 
   Larynx 
   Buccal mucosa 
   Tongue 
   Parotid  
 
0 
6 
2 
2 
2 
 
2 
 10 
3 
3 
5 
 
1 
8 
0 
1 
1 
 
 
 
 
 
0.768 
 
3 
 24 
5 
6 
8 
T classification 
   2 
   3 
   4 
 
1 
4 
7 
 
4 
 10 
9 
 
2 
8 
1 
 
 
 
0.042 
 
7 
 22 
 17 
N classification 
   0  
   1 
   2 
   3 
 
3 
0 
3 
6 
 
5 
2 
7 
9 
 
0 
2 
6 
3 
 
 
 
 
0.303 
 
8 
4 
 16 
 18 
Histological grade 
   1 
   2 
   3 
 
2 
6 
4 
 
1 
8 
 14 
 
2 
5 
4 
 
 
 
0.411 
 
5 
 19 
 22 
Total   12   23   11  -  - 
 
Table 2: Acute adverse events 
Toxicities  Grade 0-2 (%)  Grade 3-4 (%) 
Gastro-intestinal     
   Anorexia   40 (87)  6 (13) 
   Diarrhea   43 (93)  3 (7) 
   Emesis    41 (89)  5 (11) 
Stomatitis/pharyngitis   32 (70)   14 (30) 
Hematologic  5 (11)   41 (89) 
   Neutropenia  8 (17)   38 (83) 
   Thrombocytopenia   44 (96)  2 (4) 
   Febrile neutropenia   43 (93)  3 (7) 
   Anemia   39 (85)  7 (15) 
 Ansari et al. 
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Discussion 
 
Historically,  before  the  taxane  era,  combination 
chemotherapy was associated with an increased re-
sponse rate but not an improved median survival time 
relative to monotherapy in the treatment of recurrent 
head and neck carcinomas. The taxanes produce sin-
gle-agent  response  rates  that  equaled  or  exceeded 
those with cisplatin and 5-fluorouracil.
15-20 
Like most tumors, locally advanced, non-metastatic 
head and neck carcinomas can be considered a system-
ic  disease  and  thus,  an  active  systemic  treatment 
should be administered. However, locoregional control 
of  locally  advanced  head  and  neck  carcinomas  is  a 
main goal of treatment.
19 It is a significant indicator for 
quality of life in this group of patients. 
In patients with locally advanced, nonmetastatic car-
cinomas of the head and neck region who are previously 
untreated,  treatment  with  cisplatin-based  combination 
chemotherapy  will  yield  major  response  rates  approxi-
mating 90%, with clinical complete response rates in the 
30% range.
15 It is also apparent that docetaxel has signifi-
cant single agent activity in locally advanced head and 
neck carcinomas, and that additional activity is seen when 
the taxane is used together with conventional best therapy 
consisting of cisplatin and 5-fluorouracil. In this study, 
the results showed good response rates for chemotherapy 
with the TPF regimen (as induction), and chemoradio-
therapy  with  acceptable  toxicities  in  locally  advanced, 
non-metastatic head and neck carcinomas. These results 
were also seen in other studies with induction chemother-
apy  (the  TPF  regimen)  and  concurrent  chemoradia-
tion.
16,17 Remnar et al.
17 in a study with 358 patients com-
pared the PF (cisplatin + 5-FU) and TPF (docetaxel + 
cisplatin  +  5-FU)  regimens  as  induction  chemotherapy 
followed by radiotherapy. They reported 54% and 68% 
response  rates  to  induction  chemotherapy  respectively. 
The median progression free survival rates were 8.2 and 
11 months and median overall survival rates were 14.2 
and 18.6 months with a significant p value, respectively. 
Similar results were also seen by Hitt et al.
21 in 382 pa-
tients that compared PF and PacPF (paclitaxel + PF) fol-
lowed by chemoradiotherapy. A large multi-institutional 
phase II trial also demonstrated equivalent and favorable 
times to local and distant progression at 91% and 87%, 
respectively,  by  adding  induction  chemotherapy  to  an 
intensive chemoradiotherapy regimen.
18  
In another study, sequential therapy with induction 
chemotherapy followed by concurrent chemoradiother-
apy in locally advanced, non-metastatic head and neck 
carcinomas suggested that it could increase a complete 
response. The  complete  response  rate  can  predict  the 
locoregional control. Therefore, induction chemotherapy 
followed  by  chemoradiotherapy  can  improve  the  out-
come of locally advanced head and neck carcinomas.
19  
In our study, although the incidence of grade 3 and 
4 neutropenia was high (89%), only 7% (3 of 46 pa-
tients) required hospitalization due to febrile neutro-
penia, the rate of this complication was higher than 
what is usually reported with the PF chemotherapy 
regimen, but the hospitalization rate is approximately 
similar  to  the  reported  rates  in  other  studies.
17,21  It 
may be related to the number of patients in this study. 
However, it seems to be better to use  prophylactic 
granulocyte  colony  stimulating  factor  (G-CSF)  for 
avoiding severe neutropenia and related morbidity. 
According to available data, current treatment guide-
lines from the National Comprehensive Cancer Network 
(NCCN)  indicate  no  role  for  induction  chemotherapy 
prior  to  planned  surgery  and  post-operative  radiation, 
and a limited role only in selected settings prior to radia-
tion.
22 However, with the incorporation of taxanes into 
induction regimens containing cisplatin and 5-FU, new-
er data suggest that the indications for induction chemo-
therapy may evolve in the near future.
23 
In summary, we concluded that the use of the TPF 
regimen  as  induction  and  adjuvant  chemotherapy 
with  concurrent  radiotherapy  and  weekly  cisplatin 
can be an effective treatment program in locally ad-
vanced,  non-metastatic  head  and  neck  carcinomas 
with acceptable toxicities. These results should be re-
evaluated in larger phase III clinical trials. 
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